NCT02906202View on ClinicalTrials.gov

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 8, 2016

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Beta-Thalassemia
Interventions
GENETIC

LentiGlobin BB305 Drug Product

LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.

Trial Locations (8)

Unknown

Oakland

Chicago

Philadelphia

Marseille

Hanover

Rome

Bangkok

London

Sponsors
All Listed Sponsors
lead

Genetix Biotherapeutics Inc.

INDUSTRY

NCT02906202 - A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype | Biotech Hunter | Biotech Hunter